Development Of Vaccinia Virus As An Expression Vector

痘苗病毒表达载体的开发

• 批准号: 6669340
• 负责人: BERNARD MOSS
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6669340
• 关键词: biotechnology; gene expression; laboratory mouse; nucleic acid sequence; polymerase chain reaction; recombinant virus; transfection /expression vector; vaccine development; vaccinia virus; vector vaccine; virus genetics

The cytoplasmic site of gene expression and use of virally encoded enzymes are distinguishing features of vaccinia virus and other poxvirus vectors that contribute to their consistent ability to express genes derived from a variety of prokaryotic, eukaryotic and viral sources. This feature, together with their ability to stably integrate and package large amounts of additional DNA, and broad host range, account for their general use as a research tool and for synthesis of recombinant proteins in mammalian cells. Recombinant vaccinia viruses are also being tested as live vaccines. During the past year, we continued to evaluate the highly attenuated modified vaccinia virus Ankara (MVA) strain as a safe vector in the laboratory and as a vector for candidate vaccines against infectious diseases and cancers. We are also testing MVA as a safe smallpox vaccine

基因表达的细胞质位点和病毒编码酶的使用是痘苗病毒和其他痘病毒载体的显着特征，这有助于它们表达源自各种原核、真核和病毒来源的基因的一致能力。这一特征，连同它们稳定整合和包装大量额外 DNA 的能力以及广泛的宿主范围，解释了它们作为研究工具和在哺乳动物细胞中合成重组蛋白的普遍用途。重组痘苗病毒也正在作为活疫苗进行测试。在过去的一年中，我们继续评估高度减毒的改良痘苗病毒安卡拉（MVA）株作为实验室中的安全载体以及作为针对传染病和癌症的候选疫苗的载体。我们还在测试 MVA 作为安全的天花疫苗

项目成果

Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge.

• DOI: 10.1016/s0264-410x(00)00121-3
• 发表时间: 2000-07
• 期刊: Vaccine
• 影响因子: 5.5
• 作者: R. Men;L. Wyatt;I. Tokimatsu;S. Arakaki;G. Shameem;R. Elkins;R. Chanock;B. Moss;C. Lai

Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy.

亚巴样疾病病毒：用于癌症基因治疗的替代复制痘病毒载体。

• DOI: 10.1128/jvi.75.21.10300-10308.2001
• 发表时间: 2001
• 期刊: Journal of virology
• 影响因子: 5.4
• 作者: Hu,Y;Lee,J;McCart,JA;Xu,H;Moss,B;Alexander,HR;Bartlett,DL
• 通讯作者: Bartlett,DL

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

通过重组复制缺陷型牛痘病毒 MVA 启动和增强对呼吸道合胞病毒的免疫力。

• DOI: 10.1016/s0264-410x(99)00257-1
• 发表时间: 1999
• 期刊: Vaccine
• 影响因子: 5.5
• 作者: Wyatt,LS;Whitehead,SS;Venanzi,KA;Murphy,BR;Moss,B
• 通讯作者: Moss,B

Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes.

通过使用表达 JEV prM 和 E 基因的高度减毒痘苗病毒 MVA 株进行免疫接种，可预防小鼠致命的日本脑炎病毒感染。

• DOI: 10.1016/s0264-410x(98)00156-x
• 发表时间: 1999
• 期刊: Vaccine
• 影响因子: 5.5
• 作者: Nam,JH;Wyatt,LS;Chae,SL;Cho,HW;Park,YK;Moss,B
• 通讯作者: Moss,B

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

• 发表时间: 2001-12
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: J. McCart;Jerrold M. Ward;John G. Lee;Yun Hu;H. Alexander;S. Libutti;B. Moss;D. Bartlett